Cargando…
Tuberculosis drug discovery in the CRISPR era
Stewart Cole and colleagues determined the complete genome sequence of Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), in 1998 [1]. This was a landmark achievement that heralded a new age in TB drug discovery. With the genome sequence in hand, drug discoverers suddenly...
Autor principal: | Rock, Jeremy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752753/ https://www.ncbi.nlm.nih.gov/pubmed/31536613 http://dx.doi.org/10.1371/journal.ppat.1007975 |
Ejemplares similares
-
Antifungal Drug Discovery: Something Old and Something New
por: Butts, Arielle, et al.
Publicado: (2012) -
Pathogen-based precision medicine for drug-resistant tuberculosis
por: Gröschel, Matthias I., et al.
Publicado: (2018) -
Phages Fight Back: Inactivation of the CRISPR-Cas Bacterial Immune System by Anti-CRISPR Proteins
por: Maxwell, Karen L.
Publicado: (2016) -
CRISPR-Cas antimicrobials: Challenges and future prospects
por: Pursey, Elizabeth, et al.
Publicado: (2018) -
Alternative Roles for CRISPR/Cas Systems in Bacterial Pathogenesis
por: Sampson, Timothy R., et al.
Publicado: (2013)